{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:09:14Z","timestamp":1784203754766,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.gassur.2026.102459","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:53:50Z","timestamp":1779346430000},"page":"102459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early postoperative carbohydrate antigen 19-9 normalization drives prognosis after pancreatic ductal adenocarcinoma resection"],"prefix":"10.1016","volume":"30","author":[{"given":"Abdulaziz","family":"Elemosho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odysseas P.","family":"Chatzipanagiotou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher","family":"Angez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Baldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areesh","family":"Mevawalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qaidar","family":"Alizai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-9870","authenticated-orcid":false,"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gassur.2026.102459_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","article-title":"Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy","volume":"12","author":"Sarantis","year":"2020","journal-title":"World J Gastrointest Oncol"},{"issue":"4","key":"10.1016\/j.gassur.2026.102459_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70162","article-title":"Pancreatic cancer: pathogenesis and clinical studies","volume":"6","author":"Zhou","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.gassur.2026.102459_bib3","series-title":"Cancer facts and figures","year":"2025"},{"issue":"10","key":"10.1016\/j.gassur.2026.102459_bib4","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3390\/cancers17101607","article-title":"Unraveling the burden of pancreatic cancer in the 21st century: trends in incidence, mortality, survival, and key contributing factors","volume":"17","author":"Zottl","year":"2025","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.gassur.2026.102459_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.04.009","article-title":"Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: a Bi-institutional validated risk classification","volume":"49","author":"van Oosten","year":"2023","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"10.1016\/j.gassur.2026.102459_bib6","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","article-title":"Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial","volume":"154","author":"Jones","year":"2019","journal-title":"JAMA Surg"},{"issue":"3","key":"10.1016\/j.gassur.2026.102459_bib7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/SLA.0000000000005184","article-title":"Prognosis associated with CA19-9 response dynamics and normalization during neoadjuvant therapy in resected pancreatic adenocarcinoma","volume":"277","author":"Newhook","year":"2023","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.gassur.2026.102459_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4240\/wjgs.v12.i12.468","article-title":"Carbohydrate antigen 19-9 - tumor marker: past, present, and future","volume":"12","author":"Lee","year":"2020","journal-title":"World J Gastrointest Surg"},{"issue":"5","key":"10.1016\/j.gassur.2026.102459_bib9","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1007\/s12032-012-0278-9","article-title":"Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer","volume":"29","author":"Martin","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.gassur.2026.102459_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.651119","article-title":"Predicting adverse pathologic features and clinical outcomes of resectable pancreas cancer with preoperative CA 19-9","volume":"11","author":"Kowalchuk","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.gassur.2026.102459_bib11","doi-asserted-by":"crossref","first-page":"8906","DOI":"10.1245\/s10434-025-18084-0","article-title":"Favorable response defined by CA19-9 reduction after neoadjuvant treatment for pancreatic cancer","volume":"32","author":"Ashitomi","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.gassur.2026.102459_bib12","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/SLA.0000000000003049","article-title":"Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer","volume":"271","author":"Tsai","year":"2020","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.gassur.2026.102459_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.bjc.6602687","article-title":"Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer","volume":"93","author":"Ko","year":"2005","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.gassur.2026.102459_bib14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.hpb.2018.09.006","article-title":"CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts","volume":"21","author":"Laurent","year":"2019","journal-title":"HPB"},{"issue":"4","key":"10.1016\/j.gassur.2026.102459_bib15","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.21037\/jgo-22-310","article-title":"Validation of a genotype-based algorithm that identifies individuals with low, intermediate, and high serum CA19-9 levels in cancer-free individuals and in patients with colorectal cancer","volume":"13","author":"Wannhoff","year":"2022","journal-title":"J Gastrointest Oncol"},{"issue":"6","key":"10.1016\/j.gassur.2026.102459_bib16","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jhep.2013.08.005","article-title":"FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis","volume":"59","author":"Wannhoff","year":"2013","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.gassur.2026.102459_bib17","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/jcm12041596","article-title":"Correlation of UGT1A1 gene polymorphisms or prior irinotecan treatment and treatment outcomes of nanoliposomal-irinotecan plus 5-fluorouracil\/leucovorin for pancreatic ductal adenocarcinoma: a multicenter, retrospective cohort study (HGCSG2101)","volume":"12","author":"Harada","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.gassur.2026.102459_bib18","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1007\/s12325-022-02091-8","article-title":"Analysis of a real-world progression variable and related endpoints for patients with five different cancer types","volume":"39","author":"Torres","year":"2022","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.gassur.2026.102459_bib19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMsr1809937","article-title":"The \u201cAll of Us\u201d research program","volume":"381","author":"All of Us Research Program Investigators","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.gassur.2026.102459_bib20","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1245\/s10434-010-1397-1","article-title":"Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease","volume":"18","author":"Abdel-Misih","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.gassur.2026.102459_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fonc.2013.00155","article-title":"Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy","volume":"3","author":"Pelzer","year":"2013","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.gassur.2026.102459_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.hpb.2019.06.012","article-title":"Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival","volume":"22","author":"Heger","year":"2020","journal-title":"HPB"},{"issue":"6","key":"10.1016\/j.gassur.2026.102459_bib23","doi-asserted-by":"crossref","DOI":"10.5306\/wjco.v16.i6.105849","article-title":"Advances in neoadjuvant therapy for pancreatic cancer: current trends and future directions","volume":"16","author":"Wu","year":"2025","journal-title":"World J Clin Oncol"},{"issue":"24","key":"10.1016\/j.gassur.2026.102459_bib24","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.3390\/cancers15245881","article-title":"Therapy of locally advanced and oligometastatic pancreatic adenocarcinoma","volume":"15","author":"Wahler","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.gassur.2026.102459_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrae087","article-title":"Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials","volume":"8","author":"Aliseda","year":"2024","journal-title":"BJS Open"},{"issue":"9","key":"10.1016\/j.gassur.2026.102459_bib26","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.hpb.2025.05.007","article-title":"Survival prediction for CA19-9 non-producers with resected pancreatic cancer","volume":"27","author":"Alvikas","year":"2025","journal-title":"HPB"},{"issue":"4","key":"10.1016\/j.gassur.2026.102459_bib27","first-page":"900","article-title":"Lewis antigen-negative pancreatic cancer: an aggressive subgroup","volume":"56","author":"Liu","year":"2020","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102459_bib28","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1186\/s12885-022-10026-3","article-title":"Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes","volume":"22","author":"Jiang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.gassur.2026.102459_bib29","article-title":"Prognostic effect of age in resected pancreatic cancer patients: a propensity score matching analysis","volume":"12","author":"Xu","year":"2022","journal-title":"Front Oncol"}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X2600140X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X2600140X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:43:40Z","timestamp":1784202220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X2600140X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1091255X2600140X"],"URL":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102459","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early postoperative carbohydrate antigen 19-9 normalization drives prognosis after pancreatic ductal adenocarcinoma resection","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Society for Surgery of the Alimentary Tract.","name":"copyright","label":"Copyright"}],"article-number":"102459"}}